Immunological markers for predicting the response to immunotherapy in non-small cell lung cancer
| Autor: | A. A. Musaelyan, S. V. Lapin, M. A. Urtenova, S. V. Odintsova, I. V. Chistyakov, A. M. Ulitin, N. T. Ismanbaev, A. L. Akopov, S. V. Orlov |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Успехи молекулярной онкологии, Vol 9, Iss 2, Pp 79-88 (2022) |
| Druh dokumentu: | article |
| ISSN: | 2313-805X 2413-3787 |
| DOI: | 10.17650/2313-805X-2022-9-2-79-88 |
| Popis: | Itroduction. Immune checkpoint inhibitors have become the standard of care for patients with advanced non-small cell lung cancer. However, despite the determination of programmed death-ligand 1 expression in clinical practice, which determines the effectiveness of therapy, up to 80 % of patients with non-small cell lung cancer do not respond to treatment.The study objective – investigation of the prognostic role of clinical and immunological markers during immune checkpoint inhibitor monotherapy in ≥2 lines in patients with advanced non-small cell lung cancer.Materials and methods. The study included 45 patients with advanced non-small cell lung cancer receiving programmed cell death 1 / programmed death-ligand 1 inhibitors in monotherapy in 2 and subsequent lines (Group 1), as well as 30 patients with advanced non-small cell lung cancer receiving first-line chemotherapy (Group 2). All patients from 2 groups did not have autoimmune diseases before starting treatment. The determination of autoantibodies, β-2-microglobulin, neopterin, interleukin 6, interleukin 18 and the allelic variant of HLA-DRB1 in patients in the Group 1 was carried out 2 months after the start of therapy, and in the Group 2 – before the start of the next chemotherapy cycle.Results. In Group 1, the presence of EGFR / ALK mutations is an independent predictor of shorter progression-free survival (p = 0.018). Also, in the univariate analysis, neutrophil-lymphocyte ratio |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|